These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37678511)

  • 21. Novel Preclinical Patient-Derived Lung Cancer Models Reveal Inhibition of HER3 and MTOR Signaling as Therapeutic Strategies for NRG1 Fusion-Positive Cancers.
    Odintsov I; Mattar MS; Lui AJW; Offin M; Kurzatkowski C; Delasos L; Khodos I; Asher M; Daly RM; Rekhtman N; de Stanchina E; Ganji G; Ladanyi M; Somwar R
    J Thorac Oncol; 2021 Jul; 16(7):1149-1165. PubMed ID: 33839363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population.
    Pan Y; Zhang Y; Ye T; Zhao Y; Gao Z; Yuan H; Zheng D; Zheng S; Li H; Li Y; Jin Y; Sun Y; Chen H
    J Thorac Oncol; 2019 Nov; 14(11):2003-2008. PubMed ID: 31382039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
    Choi BK; Fan X; Deng H; Zhang N; An Z
    Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.
    Jones MR; Lim H; Shen Y; Pleasance E; Ch'ng C; Reisle C; Leelakumari S; Zhao C; Yip S; Ho J; Zhong E; Ng T; Ionescu D; Schaeffer DF; Mungall AJ; Mungall KL; Zhao Y; Moore RA; Ma Y; Chia S; Ho C; Renouf DJ; Gelmon K; Jones SJM; Marra MA; Laskin J
    Ann Oncol; 2017 Dec; 28(12):3092-3097. PubMed ID: 28950338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.
    Younes M; Wu Z; Dupouy S; Lupo AM; Mourra N; Takahashi T; Fléjou JF; Trédaniel J; Régnard JF; Damotte D; Alifano M; Forgez P
    Oncotarget; 2014 Sep; 5(18):8252-69. PubMed ID: 25249545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NRG1-dependent activation of HER3 induces primary resistance to trastuzumab in HER2-overexpressing breast cancer cells.
    Yang L; Li Y; Shen E; Cao F; Li L; Li X; Wang X; Kariminia S; Chang B; Li H; Li Q
    Int J Oncol; 2017 Nov; 51(5):1553-1562. PubMed ID: 29048656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RETRACTED: The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor.
    Brand TM; Iida M; Corrigan KL; Braverman CM; Coan JP; Flanigan BG; Stein AP; Salgia R; Rolff J; Kimple RJ; Wheeler DL
    Sci Signal; 2017 Jan; 10(460):. PubMed ID: 28049763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
    Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
    Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transcriptional activation of cyclin D1 via HER2/HER3 contributes to EGFR-TKI resistance in lung cancer.
    Liu B; Chen D; Chen S; Saber A; Haisma H
    Biochem Pharmacol; 2020 Aug; 178():114095. PubMed ID: 32535106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients.
    Yun S; Koh J; Nam SK; Park JO; Lee SM; Lee K; Lee KS; Ahn SH; Park DJ; Kim HH; Choe G; Kim WH; Lee HS
    Gastric Cancer; 2018 Mar; 21(2):225-236. PubMed ID: 28573357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
    Cadranel J; Liu SV; Duruisseaux M; Branden E; Goto Y; Weinberg BA; Heining C; Schlenk RF; Cheema P; Jones MR; Drilon A; Trombetta D; Muscarella LA; Tolba K; Gounant V; Cseh A; Solca F; Laskin JJ; Renouf DJ
    Oncologist; 2021 Jan; 26(1):7-16. PubMed ID: 32852072
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
    Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
    Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
    Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
    Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
    Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
    Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.
    Laskin J; Liu SV; Tolba K; Heining C; Schlenk RF; Cheema P; Cadranel J; Jones MR; Drilon A; Cseh A; Gyorffy S; Solca F; Duruisseaux M
    Ann Oncol; 2020 Dec; 31(12):1693-1703. PubMed ID: 32916265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Model-based analysis of HER activation in cells co-expressing EGFR, HER2 and HER3.
    Shankaran H; Zhang Y; Tan Y; Resat H
    PLoS Comput Biol; 2013; 9(8):e1003201. PubMed ID: 23990774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The G Protein-Coupled Receptor PAC1 Regulates Transactivation of the Receptor Tyrosine Kinase HER3.
    Moody TW; Lee L; Jensen RT
    J Mol Neurosci; 2021 Aug; 71(8):1589-1597. PubMed ID: 32964398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mig6 not only inhibits EGFR and HER2 but also targets HER3 and HER4 in a differential specificity: Implications for targeted esophageal cancer therapy.
    Zhong H; He J; Yu J; Li X; Mei Y; Hao L; Wu X
    Biochimie; 2021 Nov; 190():132-142. PubMed ID: 34293452
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The HER family as therapeutic targets in colorectal cancer.
    Ye P; Wang Y; Li R; Chen W; Wan L; Cai P
    Crit Rev Oncol Hematol; 2022 Jun; 174():103681. PubMed ID: 35462030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HER3/ErbB3, an emerging cancer therapeutic target.
    Zhang N; Chang Y; Rios A; An Z
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):39-48. PubMed ID: 26496898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.